leisure time -WSS

leisure time

author：focus 2025-08-12 06:42:38 - browse：61846

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

Wikipedia

WSS

A $475,000 price tag for a new cancer drug: crazy or meh?

ARCH Venture Partners is raising $3 billion for a life sciences fund

Cognito secures funding to test medical device for Alzheimer's

Quicker fix for pulse oximeters urged during FDA public meeting

Caribou posts encouraging results on off

Biden administration opens offers in Medicare drug price negotiations

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Jerome Adams on the need for new antivirals for Covid

A new ‘biological computer' targets cancer while sparing healthy cells

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare drug price negotiation’s day in court

Trump demands the U.S. pay no more for drugs than other countries … again

Cybersecurity threat forces Lurie Children's to take systems offline

How one medical school became remarkably diverse

Covid misinformation case heads to Supreme Court

George Santos makes 1st court appearance after pleading not guilty to 13 counts

After a decade, new Gardasil ad campaign gets it (mostly) right

explore

Woodcock on FDA’s accelerated approval and her next chapter

US jobless claims fall again as labor market continues to flash strength

Congressmen charge Covid hearing ‘could have been an email’

Vertigo drug brings hope for rare neuron disorder, Niemann

'CMA Fest' 2023: How to watch, who is performing and more

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

hotspot

Wikipedia

knowledge

knowledge